Research
Hormonal
Testosterone replacement therapy has no significant effect on memory, cognitive function, or prostate-specific antigen (PSA) levels in older hypogonadal men over 12 months.
Based on this study, testosterone therapy did not improve memory or cognitive function, nor did it significantly change PSA levels in men without existing prostate disease. Do not expect cognitive benefits from this treatment.
GoodRefutesHIGH confidence
Testosterone had no effect on memory, recall, or verbal fluency tests... PSA did not change significantly with testosterone compared with controls throughout the study.
Why this rating
RCT design, clear null results for these specific endpoints.
Source
Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Rahmawati Sih et al. · The Journal of Clinical Endocrinology & Metabolism · 1997
DOI 10.1210/jcem.82.6.3988
rct · n=32Cited 895×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Testosterone replacement therapy (200 mg testosterone cypionate biweekly) significantly improves upper body strength (grip strength) in older hypogonadal men over a 12-month period.Good
- Testosterone replacement therapy significantly decreases serum leptin levels in older hypogonadal men, suggesting a hormonal modulation of adiposity regulation.Good
- Testosterone replacement therapy increases hemoglobin and hematocrit levels in older hypogonadal men, requiring monitoring for polycythemia.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →